Trial · NCT04771780
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence rates of all adverse events and adverse drug reactions that occurred or worsened after the initiation of KHK7791 treatment for 52 weeks. | Dose period Week 1~52 | To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia. |
| Secondary | Achievement of at least 30% change of the total number of daily prescription tablets of phosphorus binders and KHK7791 from baseline in the last 3 weeks of the final assessment. | Week 1~52 | To investigate the efficacy of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in hyperphosphatemic subjects undergoing hemodialysis. Important secondary endpoint |
| Secondary | Total daily prescription of phosphate binders and KHK7791 tablets, such as tablet counts, at each time point after the start of treatment. | Week 1~52 | |
| Secondary | Achievement of at least 30% change of the total number of daily prescription tablets of phosphorus binders and KHK7791 from baseline, at each time point after the start of treatment. | Week 1~52 | |
| Secondary | The change of total daily prescription of phosphate binders and KHK7791 tablets, such as tablet counts, at each time point after the start of treatment. | Week 1~52 | |
| Secondary | The rate of change of total daily prescription of phosphate binders and KHK7791 tablets, such as tablet counts, at each time point after the start of treatment. | Week 1~52 | |
| Secondary | Concentration of serum phosphorous levels values at each time point. | Week 1~52 | |
| Secondary | Change of serum phosphorous levels from baseline values at each time point. | Week 1~52 | |
| Secondary | Achievement/failure of the target serum phosphorus level (serum phosphorus level: ≤ 6.0). | Week 1~52 | |
| Secondary | Time when the target serum phosphorus level (serum phosphorus level: ≤ 6.0) was achieved. | Week 1~52 | |
| Secondary | Achievement/failure of the target serum phosphorus level (serum phosphorus level: ≤ 5.5). | Week 1~52 | |
| Secondary | Time when the target serum phosphorus level (serum phosphorus level: ≤ 5.5) was achieved. | Week 1~52 | |
| Secondary | Concentrations of such as Ca × P product levels at each time point. | Week 1~52 | |
| Secondary | Changes of such as Ca × P product levels from baseline values at each time point. | Week 1~52 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04771780/registered